News
12-10-2009, 06:12 AM
YM BioSciences Inc., today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities.
More... (http://www.news-medical.net/news/20091210/YM-BioSciences-announces-results-of-collaborative-antibody-development-program.aspx)
More... (http://www.news-medical.net/news/20091210/YM-BioSciences-announces-results-of-collaborative-antibody-development-program.aspx)